Abstract：
UNASSIGNED: There are limited data regarding gamma-aminobutyric acid (GABA) allosteric modulator sleep-aid medications in persons with depression, insomnia, and suicidal ideation (SI).
UNASSIGNED: This secondary analysis examined the relationship of age to insomnia and the impact of age on the treatment of insomnia with zolpidem extended-release (zolpidem-ER) in depressed suicidal patients. A prior report found that the addition of zolpidem-ER promoted significantly superior reductions in global severity of insomnia in depressed outpatients with insomnia and SI over 8 weeks, but here we report the differences among early, middle, and late insomnia.
UNASSIGNED: This secondary analysis examined the three early, middle, and late insomnia items of the Hamilton Rating Scale for Depression (HRSD) and their relationship to age and responsiveness to treatment with zolpidem-ER. One hundred and three patients with major depression, SI, and insomnia received open-label serotonin reuptake inhibitors and were randomly allocated 1:1 to receive zolpidem-ER or placebo at bedtime. Results: Older age at baseline was associated with worse middle and late insomnia, but not with early insomnia. Subsequent treatment with zolpidem-ER produced superior improvement in early and middle insomnia, but not late insomnia.
UNASSIGNED: These findings are consistent with the known age-related advancement of sleep timing in the general population and depressed outpatients and with the expected effects of a short half-life GABA allosteric modulator sleep aid. By implication, prescribers of pharmacologic treatment of insomnia in depressed patients should consider an alternative to zolpidem-ER when late insomnia is a concern.Trial registration number: ClinicalTrials.gov Identifier: NCT01689909.
UNASSIGNED: This secondary analysis examined the relationship of age to insomnia and the impact of age on the treatment of insomnia with zolpidem extended-release (zolpidem-ER) in depressed suicidal patients. A prior report found that the addition of zolpidem-ER promoted significantly superior reductions in global severity of insomnia in depressed outpatients with insomnia and SI over 8 weeks, but here we report the differences among early, middle, and late insomnia.
UNASSIGNED: This secondary analysis examined the three early, middle, and late insomnia items of the Hamilton Rating Scale for Depression (HRSD) and their relationship to age and responsiveness to treatment with zolpidem-ER. One hundred and three patients with major depression, SI, and insomnia received open-label serotonin reuptake inhibitors and were randomly allocated 1:1 to receive zolpidem-ER or placebo at bedtime. Results: Older age at baseline was associated with worse middle and late insomnia, but not with early insomnia. Subsequent treatment with zolpidem-ER produced superior improvement in early and middle insomnia, but not late insomnia.
UNASSIGNED: These findings are consistent with the known age-related advancement of sleep timing in the general population and depressed outpatients and with the expected effects of a short half-life GABA allosteric modulator sleep aid. By implication, prescribers of pharmacologic treatment of insomnia in depressed patients should consider an alternative to zolpidem-ER when late insomnia is a concern.Trial registration number: ClinicalTrials.gov Identifier: NCT01689909.
摘要：
■关于抑郁症患者的γ-氨基丁酸（GABA）变构调节剂睡眠辅助药物的数据有限，失眠,自杀意念（SI）。
■这项次要分析研究了年龄与失眠的关系以及年龄对抑郁症自杀患者唑吡坦缓释剂（唑吡坦-ER）治疗失眠的影响。先前的报告发现，唑吡坦-ER的添加在8周内促进了失眠和SI的抑郁门诊患者的整体失眠严重程度的显著降低，但是在这里我们报告早期之间的差异，中间,晚失眠症
■此二次分析检查了三个早期，中间,汉密尔顿抑郁量表（HRSD）的晚期失眠项目及其与年龄和唑吡坦-ER治疗反应性的关系。一百零三名重度抑郁症患者，SI,失眠症患者接受了开放标签的5-羟色胺再摄取抑制剂,睡前服用1:1随机分配接受唑吡坦-ER或安慰剂.结果：基线时年龄较大与中晚期失眠恶化有关，但不是早期失眠。随后用唑吡坦-ER治疗可改善早期和中期失眠，但不是晚期失眠。
■这些发现与已知的一般人群和抑郁症门诊患者中与年龄相关的睡眠时间提前以及短半衰期GABA变构调节剂睡眠辅助的预期效果一致。通过暗示，当关注晚期失眠时,药物治疗抑郁症患者失眠的处方者应考虑替代唑吡坦-ER.试验注册号：ClinicalTrials.gov标识符：NCT01689909。
■这项次要分析研究了年龄与失眠的关系以及年龄对抑郁症自杀患者唑吡坦缓释剂（唑吡坦-ER）治疗失眠的影响。先前的报告发现，唑吡坦-ER的添加在8周内促进了失眠和SI的抑郁门诊患者的整体失眠严重程度的显著降低，但是在这里我们报告早期之间的差异，中间,晚失眠症
■此二次分析检查了三个早期，中间,汉密尔顿抑郁量表（HRSD）的晚期失眠项目及其与年龄和唑吡坦-ER治疗反应性的关系。一百零三名重度抑郁症患者，SI,失眠症患者接受了开放标签的5-羟色胺再摄取抑制剂,睡前服用1:1随机分配接受唑吡坦-ER或安慰剂.结果：基线时年龄较大与中晚期失眠恶化有关，但不是早期失眠。随后用唑吡坦-ER治疗可改善早期和中期失眠，但不是晚期失眠。
■这些发现与已知的一般人群和抑郁症门诊患者中与年龄相关的睡眠时间提前以及短半衰期GABA变构调节剂睡眠辅助的预期效果一致。通过暗示，当关注晚期失眠时,药物治疗抑郁症患者失眠的处方者应考虑替代唑吡坦-ER.试验注册号：ClinicalTrials.gov标识符：NCT01689909。
